At present, gonadotropin-releasing hormone agonist (GnRHa) plus a levonorgestrel-releasing intra-uterine device (LNG-IUD) can be used as an alternative to oral/systemic progestin for the treatment of women with endometrial carcinoma and atypical endometrial hyperplasia.8 In addition, a combination of GnRHa and aromatase inhibitors has also been reported as an option for preserving fertility in women with endometrial carcinoma which achieved a favorable response.9 However, available evidence on the effective application of GnRHa-based combination treatment is limited. This evidence concerns the gene CYP19A1 and atypical endometrial hyperplasia.